Allergy to Beta-lactams: Myths, Realities and Novelties

Abstract

The label of beta-lactam (BL) allergy is frequently attributed to individuals who experience adverse reactions during treatment with penicillins or other BLs. Notably, approximately 90% of these patients, spanning pediatric and adult demographics, are found to tolerate BLs upon comprehensive allergy evaluation. This study contrasts the clinical and economic outcomes of patients labeled with BL allergy against those without such a label. The findings reveal that labeled patients often endure suboptimal outcomes, including the necessity for alternative antibiotics that are less effective, more expensive, and possess higher toxicity. This scenario contributes to extended hospital stays, escalated rates of antibiotic-resistant infections, and increased healthcare expenditure. Intriguingly, even individuals with a confirmed IgE-mediated allergy to a specific BL can often safely receive other BLs following a detailed allergy assessment. Over the past decade, multidisciplinary teams globally have made concerted efforts to expedite the removal of inappropriate BL allergy labels, focusing particularly on pediatric patients and mild reaction cases. This paper offers comprehensive insights into identifying and assessing the risk of BL allergy. It further discusses diagnostic and therapeutic strategies for patients who have previously experienced adverse reactions to BLs.